ArticleBMC cancer2025

Evaluating the efficacy and safety of bladder-sparing regimen with Disitamab Vedotin combined with Toripalimab and pelvic lymph node dissection in muscle-invasive bladder cancer patients: study protocol of a multicenter single-arm phase II trial.

Tianhang Lan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.